Primecap Management
IMNM icon

Primecap Management’s Immunome IMNM Stock Holding History

Primecap Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.1M Sell
4,581,431
-206,800
-4% -$4.43M 0.06% 157
2026
Q1 		$105M Buy
4,788,231
+102,790
+2% +$2.29M 0.08% 147
2025
Q4 		$101M Buy
4,685,441
+1,667,432
+55% +$29.3M 0.08% 148
2025
Q3 		$35.3M Sell
3,018,009
-2,201
-0.1% -$21.9K 0.03% 212
2025
Q2 		$28.1M Sell
3,020,210
-393,490
-12% -$3.23M 0.02% 226
2025
Q1 		$23M Buy
3,413,700
+3,132,900
+1,116% +$30.1M 0.02% 225
2024
Q4 		$2.98M Hold
280,800
– – ﹤0.01% 289
2024
Q3 		$4.11M Buy
280,800
+12,000
+4% +$171K ﹤0.01% 288
2024
Q2 		$3.25M Buy
268,800
+55,800
+26% +$873K ﹤0.01% 294
2024
Q1 		$5.26M Buy
+213,000
New +$4.32M ﹤0.01% 282

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management's IMNM Position: Q2 2026 in Review

Primecap Management reduced its Immunome (IMNM) stake by 4.3% in Q2 2026, selling an estimated $4.43M and leaving 4,581,431 shares worth $97.1M. The position accounts for 0.06% of the portfolio, ranked #157.

Primecap Management first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. The position peaked at $105M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Primecap Management held 4,581,431 shares of Immunome worth $97.1M as of Q2 2026.
  • Primecap Management sold 206,800 Immunome shares in Q2 2026, an estimated $4.43M.
  • Immunome made up 0.06% of Primecap Management's portfolio in Q2 2026, its #157 holding.
  • Primecap Management first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • Primecap Management's Immunome position peaked at $105M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.